

LITERATURA

1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*. 2018;131(25):2745-2760.
2. Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. *Leukemia*. 2022;36(4):1171-1175.
3. Ghia P, Pluta A, Wach M, et al. Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. *HemaSphere*. 2022;6(12):E801.
4. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. *J. Clin. Oncol.* 2021;39(31):3441-3452.
5. Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. *Am. J. Hematol.* 2019;94(12):1353-1363.
6. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. *N. Engl. J. Med.* 2014;370(11):997-1007.
7. Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. *Lancet. Oncol.* 2020;21(9):1188-1200.
8. Eichhorst B, Niemann CU, Kater AP, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. *N. Engl. J. Med.* 2023;388(19):1739-1754.
9. Seymour JF, Kipps TJ, Eichhorst BF, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. *Blood*. 2022;140(8):839-850.
10. Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. *Lancet. Oncol.* 2022;23(8):1031-1043.
11. Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. *N. Engl. J. Med.* 2023;388(4):319-332.
12. Shadman M, Flinn IW, Levy MY, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. *Lancet. Haematol.* 2023;10(1):e35-e45.
13. Kater AP, Owen C, Moreno C, et al. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. *NEJM Evid.* 2022;1(7).
14. Tam CS, Allan JN, Siddiqi T, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. *Blood*. 2022;139(22):3278-3289.
15. Mato AR, Woyach JA, Brown JR, et al. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. *N. Engl. J. Med.* 2023;389(1):33-44.



Pro vás
a vaše pacienty
vysíláme
PODCASTY

NOVĚ:

**Kdy nám zdravotní
a sociální systém podává
pomocnou ruku?**

Medicínské informace ze Solenu můžete získávat nejen v tištěné podobě, na kongresech nebo z on-line kurzů, ale máme i podcastový kanál.

Více na **www.solen.cz**



V podcastových aplikacích hledejte **HOVORY O MEDICÍNĚ**